Bamco Inc. NY cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Get Rating) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,773,014 shares of the company’s stock after selling 70,100 shares during the quarter. Bamco Inc. NY owned about 3.58% of Axonics worth $110,867,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Axonics by 32.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,073,473 shares of the company’s stock valued at $286,935,000 after buying an additional 991,055 shares in the last quarter. BlackRock Inc. grew its holdings in Axonics by 2.9% in the 3rd quarter. BlackRock Inc. now owns 3,504,942 shares of the company’s stock valued at $246,888,000 after buying an additional 97,908 shares in the last quarter. Bellevue Group AG grew its holdings in Axonics by 9.5% in the 1st quarter. Bellevue Group AG now owns 2,049,205 shares of the company’s stock valued at $128,280,000 after buying an additional 177,191 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in Axonics by 48.5% in the 3rd quarter. Lord Abbett & CO. LLC now owns 1,871,874 shares of the company’s stock valued at $131,855,000 after buying an additional 611,091 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Axonics by 8.6% in the 1st quarter. Invesco Ltd. now owns 1,171,343 shares of the company’s stock valued at $73,326,000 after buying an additional 92,445 shares in the last quarter. 97.49% of the stock is owned by institutional investors and hedge funds.
Axonics Stock Up 1.1 %
Shares of AXNX stock opened at $50.04 on Wednesday. Axonics, Inc. has a twelve month low of $46.57 and a twelve month high of $79.92. The company has a market cap of $2.52 billion, a P/E ratio of -50.55 and a beta of 0.40. The business has a fifty day simple moving average of $53.72 and a 200 day simple moving average of $57.82.
Wall Street Analyst Weigh In
AXNX has been the topic of a number of research reports. Mizuho initiated coverage on Axonics in a report on Thursday, April 13th. They issued a “buy” rating and a $75.00 price objective on the stock. CL King began coverage on Axonics in a report on Tuesday, May 23rd. They set a “buy” rating and a $75.00 target price on the stock. Truist Financial reduced their target price on Axonics from $82.00 to $73.00 and set a “buy” rating on the stock in a report on Monday, April 17th. Finally, Needham & Company LLC increased their target price on Axonics from $71.00 to $73.00 in a report on Tuesday, May 2nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, Axonics has an average rating of “Moderate Buy” and a consensus target price of $78.44.
Insider Buying and Selling
In related news, CFO Danny L. Dearen sold 2,001 shares of the company’s stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $60.01, for a total transaction of $120,080.01. Following the completion of the sale, the chief financial officer now directly owns 23,993 shares in the company, valued at approximately $1,439,819.93. The sale was disclosed in a filing with the SEC, which is available through this link. In other Axonics news, CFO Danny L. Dearen sold 7,999 shares of the stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $49.46, for a total value of $395,630.54. Following the completion of the transaction, the chief financial officer now directly owns 9,202 shares in the company, valued at $455,130.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Danny L. Dearen sold 2,001 shares of the stock in a transaction dated Thursday, April 20th. The shares were sold at an average price of $60.01, for a total value of $120,080.01. Following the completion of the transaction, the chief financial officer now owns 23,993 shares of the company’s stock, valued at $1,439,819.93. The disclosure for this sale can be found here. Insiders sold a total of 25,000 shares of company stock worth $1,344,761 in the last ninety days. 2.31% of the stock is owned by insiders.
Axonics Profile
Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction.
Featured Articles
- Get a free copy of the StockNews.com research report on Axonics (AXNX)
- As Peloton Shares Fall Over 90%, A Comeback Strategy Surges
- Inflation, The Fed, And The Summer Rally
- How to Trade Stocks Online the Right Way
- SentinelOne Stock is Down, But Is it Out?
- Oracle Has Spoken: The AI Cloud Is Bigger And Growing Faster
Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics, Inc. (NASDAQ:AXNX – Get Rating).
Receive News & Ratings for Axonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics and related companies with MarketBeat.com's FREE daily email newsletter.
